• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Platelets >The Influence of Prostaglandin E1 and Use of Inhibitor Percentage on the Correlation between the Multiplate and VerifyNow in Patients on Dual Antiplatelet Therapy
【24h】

The Influence of Prostaglandin E1 and Use of Inhibitor Percentage on the Correlation between the Multiplate and VerifyNow in Patients on Dual Antiplatelet Therapy

机译：前列腺素E1的影响及抑制剂百分比对双抗血小板治疗患者多塑和验证的相关性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Platelet function tests (PFT), such as the Multiple Electrode Analyzer (Multiplate) and VerifyNow, show little concordance in patients using antiplatelet drugs. A major difference between these tests is the use of prostaglandin E1 (PGE1) to inhibit P2Y1-platelet-receptor activation in VerifyNow and is proposed to be of influence in the discrepancy between these tests. We aimed to investigate whether the presence of PGE1 could provide an explanation for the moderate correlation and concordance between Multiplate and VerifyNow by adding PGE1 to the Multiplate ADP assay, also known as the ADP-high sensitivity (ADP-HS) assay. We also aimed to investigate whether the difference in baseline platelet function as measured by the VerifyNow and Multiplate could (partly) explain the moderate correlation between the tests, by plotting ADP assay results against baseline function as measured by the corresponding device, which is expressed as the 'inhibitor percentage.' Fifty-one patients who underwent percutaneous coronary intervention (PCI) received dual antiplatelet therapy and were considered to have a high risk of ischemic or bleeding complications were included. The addition of 20 mu l PGE1 in the Multiplate resulted in a significant reduction in Arbitrary Aggregation Units, but did not improve correlation with the VerifyNow. The correlation between VerifyNow and Multiplate inhibitor percentage was moderate. Based on these results, we concluded that neither PGE1 nor the calculation of the inhibitor percentage greatly influenced the correlation between PFTs.
机译：血小板功能测试（PFT），如多电极分析仪（Multiplate）和VerifyNow，在使用抗血小板药物的患者中几乎没有一致性。这些试验之间的一个主要差异是在VerifyNow中使用前列腺素E1（PGE1）抑制P2Y1血小板受体活化，并被认为对这些试验之间的差异有影响。我们的目的是通过将PGE1添加到多相ADP分析（也称为ADP高灵敏度（ADP-HS）中，研究PGE1的存在是否可以解释多相ADP和VerifyNow之间的中度相关性和一致性。我们还旨在研究VerifyNow和Multiplate测量的基线血小板功能差异是否可以（部分）解释测试之间的中度相关性，方法是将ADP分析结果与相应设备测量的基线功能（以“抑制剂百分比”表示）进行对比51名接受经皮冠状动脉介入治疗（PCI）的患者接受了双重抗血小板治疗，并被认为存在缺血性或出血并发症的高风险。在Multiplate中添加20μl PGE1导致任意聚合单元显著减少，但没有改善与VerifyNow的相关性。VerifyNow和多重抑制剂百分比之间的相关性中等。基于这些结果，我们得出结论，PGE1和抑制剂百分比的计算都不会对PFT之间的相关性产生重大影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号